Search Results

Press Releases

NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement

November 5, 2024

·

10 min read

Press Releases

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

July 18, 2024

·

6 min read

Press Releases

NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge

July 29, 2024

·

8 min read

Business

iTolerance, Inc. and Kadimastem Enter into Collaboration Agreement for Development of a Potential Cure for Type 1 Diabetes and Receive US $1.0 Million Grant from the BIRD Foundation

iTolerance, Inc. announced that it has entered into a research collaboration agreement with Israeli-based company, Kadimastem, to co-develop and commercialize a breakthrough and innovative regenerative technology to cure diabetes without the need for chronic immunosuppression.

May 18, 2023

·

6 min read

Kadimastem Receives Approval of Patent Registration for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in a Third Territory

Kadimastem Ltd. has been granted its third patent approval for the company’s innovative cell selection and enrichment technology and its use in the production of IsletRx, the company’s treatment and potential cure for diabetes.

September 28, 2022

·

5 min read

ILEX Medical to Invest 10 million NIS ($3.2 million) in Kadimastem

Kadimastem Ltd. announces a raise of 10 million NIS ($3.2 million) from ILEX Medical (TASE: ILX) one of the largest healthcare companies in Israel, in a private financing round.

November 29, 2021

·

7 min read

Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use in Drug Screening and the Treatment of ALS

Kadimastem Ltd., a clinical stage cell therapy company, announced that it has been granted a patent by The Israel Patent Office for its differentiated human astrocytes from human pluripotent stem cells for use in the treatment and drug screening of Amyotrophic Lateral Sclerosis.

March 9, 2021

·

3 min read

Drug Development

Kadimastem Announces Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company, announced today encouraging results of Cohort B of its Phase 1/2a clinical trial of AstroRx® for patients with Amyotrophic Lateral Sclerosis (ALS). The primary objective of the trial was to evaluate the safety of AstroRx®,

December 15, 2020

·

6 min read

Business

Kadimastem Announces Leadership Changes

Kadimastem, a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef has stepped down as Chief Executive Officer.

May 29, 2019

·

4 min read

Drug Development

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

Kadimastem Ltd., announced that its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

August 3, 2020

·

10 min read